Form 4: Adaptive Biotechnologies CCO Sells Shares for Tax Obligations

Adaptive Biotechnologies' Chief Commercial Officer, Susan Bobulsky, sold 41,338 shares of common stock at $13.17 per share to cover tax withholding obligations related to RSU vesting.

Summary

• Susan Bobulsky, Chief Commercial Officer, MRD, of Adaptive Biotechnologies Corp (ADPT), reported a transaction on March 11, 2026.
• The transaction involved the disposition of 41,338 shares of common stock.
• The shares were sold at a price of $13.17 per share.
• Following this transaction, Susan Bobulsky beneficially owns 427,775 shares of common stock.
• The sale was a 'sell to cover' transaction, mandated by the Issuer's equity incentive plans to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs), and was not a discretionary trade.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale was non-discretionary, solely for tax purposes related to RSU vesting, and does not indicate a change in management's confidence or a strategic shift.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common occurrence for executives and employees receiving equity compensation. They are typically non-discretionary sales executed to satisfy tax obligations upon the vesting of restricted stock units or the exercise of stock options, and generally do not reflect management's sentiment about the company's future prospects.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and not indicative of a change in insider sentiment.
• Employees: The transaction highlights the common practice of equity compensation and associated tax obligations within the company's incentive plans.

Key Dates

Recommendation

The transaction is a routine 'sell to cover' for tax withholding purposes, not a discretionary sale reflecting a change in the insider's view of the company's prospects. Therefore, it does not provide new information that would warrant a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Adaptive Biotechnologies, ADPT, Susan Bobulsky, Chief Commercial Officer, Insider Trading, Form 4, Stock Sale, Tax Withholding, RSU Vesting, Sell to Cover